U.S. payrolls rose by 178,000 in March, more than expected; unemployment at 4.3%

[ad_1] “TSA Is Hiring” signage at Philadelphia International Airport (PHL) in Philadelphia, Pennsylvania, US, on Monday, March 23, 2026. Matthew Hatcher | Bloomberg | Getty Images The U.S. labor market bounced back in March, with job creation much stronger than expected though the broader picture of a slow-growth labor market held intact. Nonfarm payrolls rose […]

The March jobs report will be released on Friday. Here’s what to expect

[ad_1] A “Help Wanted” sign hangs in restaurant window in Medford, Massachusetts, U.S., January 25, 2023. Brian Snyder | Reuters Nonfarm payrolls are expected to bounce back — barely — in March as the bar keeps getting lower for what constitutes a healthy labor market. The U.S. economy is projected to show job gains of […]

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison

[ad_1] Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly‘s rival pill that was approved this week, Novo Nordisk said Thursday.  Oral Wegovy demonstrated “significantly greater mean weight loss” than orforglipron, which Lilly will sell under […]

Recession odds climb on Wall Street as economy shows cracks beneath the surface

[ad_1] Vanessa Nunes | Istock | Getty Images Federal Reserve Chair Jerome Powell last week pushed back when asked whether stagflation posed a threat to the U.S. economy. His successor may face a tougher challenge, as Wall Street forecasters raise their expectations of recession, brought on in part by the Iran war and potential for […]

These 4 charts show the scale of Novo Nordisk’s woes

[ad_1] Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most valuable company. But its troubles are stacking up and today the stock trades at just a quarter of what it did at its peak less than two years ago. Pricing pressure, fierce competition, and pipeline setbacks […]

Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades

[ad_1] Analysts added to the sour mood around Novo Nordisk , racing to cut price targets on the stock, after the Danish drugmaker published disappointing trial results on what it hoped to be its next big weight loss drug. The drug, CagriSema didn’t meet the key goal of matching rival medicine Zepbound, developed by Eli […]